Comparative study of hematological parameters along with effect of chemotherapy and radiotherapy in different stages of breast cancer

Swati Shrivastava, Neelima Singh, Akshay Kumar Nigam, Sanjay Singh Chandel, Reetika Shrivastava, Sarvesh Kumar


Background: Breast cancer is one of the most common malignancies found among women in India. Haematological parameters have been shown to predict severity, mortality and treatment follow-up in breast cancer patients. The aim of the study was to compare haematological parameters along with effect of chemotherapy and radiotherapy in different stages of breast cancer patients.

Methods: Total 235 human subjects were taken in the study. Out of which 100 normal ages matched healthy subjects were considered as controls and 135 breast cancer patients subjects as cases which were further divided into their respective stages according to TNM classification.

Results: Estimation of haematological parameters was done by Sysmex Automated Hematology Analyzer Kx-21. The statistical differences between cases and control were determined by using student independent sample t-test.

Conclusions: We found hemoglobin level, polymorphs, lymphocytes, monocytes and RBC count were statistically reduce (p<0.05) while other parameters were non-significant as compared to control healthy subjects. We also found deranged haematological parameters in all four stages of breast cancer. The data also indicated that patients which were on combined therapies i.e. radio and chemo have more deranged and decreased levels of haematological parameters as compared to individual therapies.


Breast cancer, Haematological parameters, Sysmex automated haematology analyzer

Full Text:



Lodish H, Arnold BS, Lawrence Z, Paul M, David B, James ED. Molecular Cell Biology. Ed 4th, W. H. Freeman and Co. 2000.

Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF. Cancer Medicine. BC Decker Inc. 2003.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.

Benson CS, Babua SD, Radhakrishnab S, Selvamurugnac N, Sankara BR. Expression of matrix metalloproteinases in human breast cancer tissues. Dis Markers. 2013;34:395-405.

Chang R, Wong GY. Prognostic significance of marked leukocytosis in hospitalized patients. J Gen Intern Med. 1991;6:199-203.

Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991;100:1619-36.

Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-29.

Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.

Ali LO. Study effect of Breast Cancer on Some Hematological and Biochemical Parameters in Babylon Province, Iraq. 2014;9(3):20-4.

Spivak JL, Gascon P, Ludwig H.Anemia management in oncology and hematology. The Oncologist. 2009;14(1):43-56.

Croci S, Pedrazzi G, Passeri G, Delsignore R, and Ortalli I. Red cell Hb oxidation of healthy subjects compared to breast cancer patients, Anti-Cancer Res. 2002;22(5):2903-6.

Kandemir EG, Mayadagli A, Turken D, Yoylaci M, Ozturk A. Pre Treatment hemoglobin concentration is a prognostic factor in patients with early stage breast cancer. J. Int. Med. Res. 2005;33(3):319-28.

Miller B, Heilmann L. Hemorheologic variables in breast cancer patients at the time of diagnosis and during treatment. Cancer. 1988;62:350-4.

Moraes SP, Cunha A, Neto JAR, Barbosa H, Roncalatto CAP, Duarte RF. Modelo experimental de tumor de Walker. Acta Cir Brass. 2000;15:1.

Rana SAP, Kaur M, Zonunsanga B, Puri A, Kuka AS. Preoperative Peripheral Blood Count in Breast Carcinoma: Predictor of Prognosis or a Routine Test.Int J Breast Cancer. 2015;2015:5.

Ufelle SA, Ukaejiofo EO, Neboh EE, Achukwu PU, Ikekpeazu EJ, Maduka IC, Eluke B. Some hematological parameters in pre- and post-surgery breast cancer patients in Enugu, Nigeria. Int J Cur Bio Med Sci. 2012;2(1):188-90.

Porrata LF, Markovic SN. Is absolute lymphocyte count just another prognostic factor in cancer? SRX Medicine. 2010;2010:8.

Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature. 2004;43:1405-6.

Nemoto T, Han T, Minowada J, Angkur V, Chamberlain A, Dao L. Cell-mediated immune status of breast cancer patients: evaluation by skin tests, lymphocyte stimulation, and counts of rosette-forming cells. J Natl Cancer Inst. 1974;53(3):641-5.

Akinbami A, Popoola A, Adediran A, Dosunmu A, Oshinaike O, Adebola P, et al. Full blood count pattern of pre-chemotherapy breast cancer patients in Lagos, Nigeria. Caspian J Intern Med. 2013;4(1):574-9.

Zhang P, Zong Y, Liu M, Tai Y, Cao Y, Hu C. Prediction of outcome in breast cancer patients using test parameters from complete blood count. Mol Clin Oncol. 2016;4:918-24.

Pushpa Rani V. Effect of hematological changes in breast cancer among the Chennai population. IJCR. 2012;4(5):60-6.

Younis M, Abbas R, Hussain A, Mehmood SS, Hassan IU, Iqbal M, et al. Anti-breast cancer therapy may affect blood and liver cells. Bio Med Lett. 2015;1:1-4.

Williams MD, Braun LA, Cooper LM. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care. 2004;8:291-8.

Iqbal M, Younis M, Shoukat N, Shaikh S, Akram N, Abbas R, et al. Hematological study of cancer patients with radio-chemotherapy. Sci Lett. 2015;3(2):75-9.

Dolan S. Thrombocytopenia. The Royal Marsden Hospital Handbook of Cancer Chemotherapy. Brighton D, Wood M. Churchill Livingstone, London, UK. 2005.

Miller B, De Bellis D. Thrombocytopenia. The Gale Encyclopedia of Cancer 2. Longe JL. Detroit, Gale group. 2005.

Dolan S. Haemorrhagic problems In Nursing in hematological oncology, Grundy M (Ed.), Elsevier Health Sciences, London, UK. 2000:339.

Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997;90:1345-64.

Zeuner A, Pedini F, Signore M, Testa U, Pelosi E, Peschle C, et al. Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins. Blood. 2003;102:87-93.

Zeuner A, Signore M, Martinetti D, Bartucci M, Peschle C, De Maria R, et al. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. Cancer Res. 2007; 67:4767-73.